Evidence map›Paper›PMID 39440808›Full record

ReviewInfluenza and other respiratory viruses2024

Inno4Vac Workshop Report Part 2: RSV-Controlled Human Infection Model (CHIM) Strain Selection and Immune Assays for RSV CHIM Studies, November 2021, MHRA, UK.

Joanna Waldock, Rebecca J Cox, Othmar G Engelhardt, Stephanie Ascough, Albert Osterhaus, Guus F Rimmelzwaan, Martin Ludlow, John S Tregoning, Jacqueline U McDonald, Ursula J Buchholz and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joanna WaldockInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, UK.
Rebecca J CoxInfluenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
Othmar G EngelhardtInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, UK.
Stephanie AscoughDepartment of Infectious Disease, Imperial College London, London, UK.
Albert OsterhausResearch Centre for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
Guus F RimmelzwaanResearch Centre for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
Martin LudlowResearch Centre for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
John S TregoningDepartment of Infectious Disease, Imperial College London, London, UK.
Jacqueline U McDonaldInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, UK.
Ursula J BuchholzRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA.
Rienk E JeeningaViroclinics Biosciences B.V., Rotterdam, The Netherlands.
Charles SandeKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Christopher ChiuDepartment of Infectious Disease, Imperial College London, London, UK.

Funding

Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related VirusesZIAAI000326 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BUCHHOLZ, URSULA · 2009 to 2025
$33.1M
Innovative Medicines Initiative 101007799Intramural NIH HHS ZIA AI000326NHLBI NIH HHS ZIA AI000326
6 · The paper itself

Abstract

Controlled human infection models (CHIMs) are a critical tool for the understanding of infectious disease progression, characterising immune responses to infection and rapid assessment of vaccines or drug treatments. There is increasing interest in using CHIMs for vaccine development and an obvious need for widely available and fit-for-purpose challenge agents. Inno4Vac is a large European consortium working towards accelerating and de-risking the development of new vaccines, including development of CHIMs for influenza, respiratory syncytial virus and Clostridium difficile. This report (in two parts) summarises a workshop held at the MHRA in 2021, focused on how to select CHIM candidate strains of influenza and respiratory syncytial virus (RSV) based on desirable virus characteristics and which immune assays would provide relevant information for assessing pre-existing and post-infection immune responses and defining correlates of protection. This manuscript (part 2) summarises presentations and discussions centred around RSV CHIMs and immune assays (an additional manuscript summarises influenza CHIM and immune assays: Inno4Vac workshop report Part 1: Controlled human influenza virus infection model (CHIVIM) strain selection and immune assays for CHIVIM studies, November 2021, MHRA, UK).

Indexed as

Respiratory Syncytial Virus InfectionsAnimalsHumansInfluenza, HumanInfluenza VaccinesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus VaccinesUnited KingdomVaccine DevelopmentInfluenza VaccinesRespiratory Syncytial Virus Vaccinescontrolled human infection model (CHIM)correlates of protection (CoP)immune assaysrespiratory syncytial virus (RSV)respiratory viruses

Identifiers

PMID39440808
PMCPMC11497170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.